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A B S T R A C T
Background
Specialist nursing roles to manage stable disease populations are being used to meet the needs of both patients and health services. With
increasing cost pressures on health departments, alternative models such as nurse-led care are gaining momentum as a substitute for
traditional doctor-led care. This review evaluates the safety, effectiveness, and health outcomes of nurses practising in autonomous roles
while using advanced practice skills, within the context of bronchiectasis management in subacute, ambulatory, and/or community
care.
Objectives
To compare the effectiveness of nurse-led care versus doctor-led care in the management of stable bronchiectasis.
Search methods
We searched the Cochrane Airways Group Specialised Register and bibliographies of selected papers in addition to grey literature such
as electronic clinical trials registries. Searches were current as of March 2018.
Selection criteria
Randomised controlled trials were eligible for inclusion in the review.
Data collection and analysis
Two reviewers extracted and entered data from included studies. Primary outcomes were numbers of exacerbations requiring treatment
with antibiotics, hospital admissions, and emergency department attendances.
Main results
We included one United Kingdom (UK) study in the review. In this randomised controlled trial, a total of 80 participants, with a mean
age of 58 years, were treated for 12 months by a specialist nurse or doctor, then were crossed over to the other clinician for the next
12 months. Two participants died during the study period. Six participants failed to cross over to nurse-led care because of unstable
bronchiectasis. Overall, the level of study completion was high.
Data show no difference in the numbers of exacerbations requiring treatment with antibiotics (rate ratio 1.09, 95% conﬁdence interval
(CI) 0.91 to 1.30, 80 participants, moderate-certainty evidence). Investigators reported more hospital admissions in the nurse-led care
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group (rate ratio 1.52, 95% CI 1.04 to 2.23, 80 participants, moderate-certainty evidence) and did not report emergency department
attendance.
For secondary outcomes, participants in the nurse-led care group used more healthcare resources during the ﬁrst year of the trial.
Increased admissions and greater use of resources made treatment costs for nurse-led groups’ higher. Total costs for both years of the
study were £8,464 and £5,228 for nurse-led care compared with doctor-led care. However, by the second year, treatment costs were
almost equitable between the two groups, which may reﬂect the nurses’ learning of how to better treat people with bronchiectasis. No
statistically signiﬁcant changes were observed in quality of life, exercise capacity, mortality, or lung function. Wide conﬁdence intervals
led to uncertainty regarding these results. Adverse events were not an outcome for this review.
Authors’ conclusions
This update of the review shows that only one trial met review criteria. Review authors were unable to demonstrate effectiveness of nurse-
led care compared with doctor-led care on the basis of ﬁndings of a single study. The included study reported no signiﬁcant differences,
but limited evidence means that differences in clinical outcomes between nurse-led care and usual care within the setting of a specialist
clinic remain unclear. Further research is required to determine whether nurse-led care is cost-effective, if guidelines and protocols for
bronchiectasis management are followed does this increases costs and how effective nurse-led management of bronchiectasis is in other
clinical settings such as inpatient and outreach.
P L A I N L A N G U A G E S U M M A R Y
Nurse specialist care for bronchiectasis
Background
Bronchiectasis is a long-term lung disease. The main symptom is cough that produces phlegm and results in recurrent chest infections.
As the disease gets worse, people have poor quality of life and eventually may develop respiratory failure - a condition in which the
body is not able to control oxygen and carbon dioxide levels properly.
Review question
We wanted to ﬁnd out if nurses are able to manage the care of people with bronchiectasis as well as doctors. We looked for randomised
controlled trials comparing nurse-led care with doctor-led care.
Study characteristics
We found one study from the United Kingdom involving 80 people with bronchiectasis. The study was completed in 2002, when
management of bronchiectasis was different from today. Participants were divided into two groups: One group of outpatients was
observed for a 12-month period under the care of the specialist nurse, and the other under care of the doctor. After 12 months, these
participants swapped groups.
Key results
We found no signiﬁcant differences between nurse-led and doctor-led care in terms of lung function, infective ﬂareups (exacerbations),
or quality of life. In the ﬁrst year of the study we noted increased costs for nurse-led care with more hospital admissions and greater use
of antibiotic injections.
Certainty of evidence
The certainty of evidence in the one included study was satisfactory, given that the study design meant participants knew which group
they belonged to.
Bottom line
More research is required to determine how nurse specialists compare with doctors in providing safe and effective treatment for patients
with stable bronchiectasis.
This Cochrane plain language summary was up-to-date as of March 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Nurse- led care compared with doctor- led care for management of bronchiectasis
Patient or population: management of bronchiectasis
Setting: outpat ient
Intervention: nurse-led care
Comparison: doctor-led care
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with doctor- led
care
Risk with nurse- led
care
Exacerbat ions
requiring treatment
with ant ibiot ics (per pa-
t ient per year)
Assessed by clinician
ident if ied or part icipant
self -reported
Follow-up: 12 months
Mean rate of infect ive
exacerbat ions was 3.1
per pat ient per year
0.28 per pat ient per
year higher
(95%CI 0.28 lower to 0.
97 higher)
1.09 (95% CI 0.91 to 1.
30)
80
(1 RCT)
⊕⊕©©
LOWa,b
Hospital admissions
(per pat ient per year).
Follow-up: 12 months
Mean admission per pa-
t ient per year was 1.02.
1.55 per pat ient per
year higher
(1.06 higher to 2.27
higher)
1.52 (95% CI 1.03 to 2.
23)
80
(1 RCT)
⊕⊕©©
LOWa,b
More admissions in
nurse-led care. All
nurse-led care admis-
sions approved by con-
sultant. Protocol fol-
lowed by nurse regard-
ing management
Emergency department
attendance
See comment. See comment. See comment. See comment. See comment. Not reported
Mortality Two part icipants died -1 f rom each care group -af ter 12-month assessment See comment. ⊕⊕©©
LOWa,b
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Cost-ef fect iveness
Total cost for durat ion
of study and dif ference
in cost for f irst and sec-
ond years
Cost scale: £ per part ic-
ipant
Total costs £5428
Cost dif f erence £274
higher in second year
Total costs £8464
Cost dif f erence £1940
lower in second year
⊕⊕©©
LOWa,b,c
Costs may be reduced
over t ime through a
learning ef fect.
Quality of lif e, mea-
sured with SGRQ - total
scores
Lower scores indicat-
ing improved respira-
tory health
Scale f rom 0 to 100
Follow-up: 12 months
Unreported MD 1.7 higher
(4 lower to 0.6 higher)
79
(1 RCT)
⊕⊕©©
LOWa,b
Part icipants reported
fewer symptoms and
less impact on daily
lif e with nurse-led care,
but data show no clin-
ical or stat ist ically sig-
nif icant dif f erences be-
tween nurse-led and
doctor-led care
Exercise capacity:
12MWT
Assessed with dis-
tance, metres
Follow-up: 12 months
Mean exercise capac-
ity: 12MWT was 746 m.
MD 18 m greater
(13 lower to 49 higher)
80
(1 RCT)
⊕⊕©©
LOWa,b
No signif icant dif -
ferences in distance
walked between nurse-
led and doctor-led care
FEV1
assessed with % pre-
dicted
Scale f rom 0 to 100
Follow-up: 12 months
Mean FEV1 was 69.5%
predicted.
MD 0.2% predicted
higher
(1.6% predicted lower
to 2% predicted higher)
80
(1 RCT)
⊕⊕©©
LOWa,b
Nil signif icant dif f er-
ences in percentage
predicted FEV1 be-
tween nurse-led and
doctor-led care
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
12MWT: 12-minute walk test; CI: conf idence interval; FEV1: f orced expiratory volume in one second; MD: mean dif ference; RCT: randomised controlled trial; SGRQ: St. George’s
Respiratory Quest ionnaire
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GRADE Working Group grades of evidence.
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aCannot rule out carryover ef fects f rom cross-over trial. No reported information at f irst 12-month t ime period before cross-
over. May have had a learned ef fect that resulted in fewer exacerbat ions and hospitalisat ions and better quality of lif e. This
may have led to better lung funct ion and exercise capacity. Marked down one point for risk of bias.
bAge of study, small number of part icipants, and uncertainty, with some results based on wide conf idence intervals. Marked
down one point for imprecision.
cCannot rule out select ive report ing with the decision not to cross-over 6 part icipants af ter f irst 12 months. No longer
considered stable bronchiectasis. Already marked down for risk of bias previously, so not downgraded again based on this
reason.
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B A C K G R O U N D
Description of the condition
Bronchiectasis is a lung condition characterised by the radiological
ﬁnding of permanent abnormal dilatation of one or more bronchi
(Boyton 2012; Kim 2012; King 2011). Patients with bronchiec-
tasis have a persistent productive cough and recurrent infection
and often develop airway colonisation with opportunistic micro-
organisms (Abo-Leyah 2017; McShane 2013).
Diagnosis of bronchiectasis is conﬁrmed by high-resolution com-
puted tomography (HRCT) (King 2010). Diagnosis is based on
this radiological ﬁnding along with presenting clinical symptoms
of cough and sputum production (Abo-Leyah 2017; Feldman
2011).
Many causes of bronchiectasis are known. These include damage
to the airway associated with foreign body, past signiﬁcant respi-
ratory infections, genetic disorders, abnormal host defences, and
autoimmune disease (Katzenstein 1982; Kim 2012). The under-
lying cause may also be idiopathic (Boyton 2012).
Clinically, patients present with symptoms of increased sputum
production and recurrent infections (Kim 2012; King 2010).
Other symptoms may include shortness of breath, mild to mod-
erate airﬂow limitation, and haemoptysis. As the condition pro-
gresses, patients may experience poorer health status and quality
of life and increased functional disability (Boyton 2012; Wong
2012). This may result in weight loss and increased airﬂow ob-
struction andmay lead to further complications of respiratory fail-
ure and right-sided heart failure (Boyton 2012).
Prevalence
Previously referred to as an orphan disease and thought to be un-
common, bronchiectasis may be more common than was previ-
ously thought, but its true incidence remains unclear (Chalmers
2017; Chang 2008). In the past, global incidence data for
bronchiectasis were derived from hospital admission coding
(McShane 2013; Ringshausen 2013). Disease registries have been
established globally over the past ﬁve years; these provide a more
accurate picture of bronchiectasis populations around the world
(Chalmers 2017). In the UK, the incidence of bronchiectasis
in 2013 was 35.17/100,000 women and 26.92/100,000 men
(Quint 2016). Point prevalence data for the same year show
that cases of bronchiectasis in women (566.1/100,000) and men
(485.5/100,000) younger than 40 remain uncommon and reach
higher prevalence in older age (Quint 2016). In the United States
bronchiectasis prevalence appears to have an 8.74% annual in-
crease with the number of aging bronchiectasis patients reported
to be contributing to this rise (Aksamit 2017). Sex and age may
contribute to the pathogenesis of bronchiectasis, andmore females
and elderly individuals are given the diagnosis (King 2010).
Bronchiectasis occurs independently of other respiratory diseases
but may coexist and may have similar features to other respiratory
chronic diseases, leading to a possible delay in diagnosis (Chang
2015; King 2010). Researchers have noted overlap of chronic ob-
structive pulmonary disease (COPD) and bronchiectasis, and phe-
notyping in both diseases has become a topic of discussion. Addi-
tional investigations are required to determine the underlying re-
lationships and interactions of coexisting respiratory diseases (Liu
2014: Martinez-Garcia 2017).
Bronchiectasis prevalence is higher in indigenous population
groups, and bronchiectasis has been identiﬁed as an important
cause of childhood morbidity (Chang 2010). Indigenous exam-
ples of higher prevalence include Aboriginal Australians (1470
cases/100,000 population), Alaskan Natives (1400 cases/100,000
population), and Canadian Inuit in the Qikiqtani Region (202/
100,000) (Boyton 2012; Chang 2010; Das 2015). Higher mor-
tality rates have been reported among Paciﬁc (17.8/100,000) and
Maoris children (4.8/100,000) than among New Zealand chil-
dren of European and other ethnicity; however signiﬁcant mortal-
ity does not seem to begin until adulthood (Twiss 2005). Child-
hood lower respiratory tract infections and environmental factors
of tobacco exposure and overcrowding in the home are thought
to contribute to higher rates of bronchiectasis (Das 2015).
Management
There remains a lack of certain evidence from large clinical research
trials to support bronchiectasis management (Chalmers 2017).
Development and evolution of guidelines for the management
of bronchiectasis have continued since the release of the Span-
ish guideline in 2008 (Chalmers 2017; Martinez-Garcia 2018).
Guidelines based on available evidence and expert opinion have
been produced by the British Thoracic Society (BTS) and The
Australian and New Zealand Thoracic Society (TSANZ) (Chang
2015; Pasteur 2010), and,more recently, the EuropeanRespiratory
Society, the Spanish Society of Pulmonology, and the Saudi Tho-
racic Society (Al-Jahdali 2017; Martinez-Garcia 2018; Polverino
2017). Management includes symptom control, prevention of
acute exacerbations/infections, and limitation of disease progres-
sion (Feldman 2011; King 2010; Lavery 2007), and aims to sup-
port a healthy lifestyle incorporating good nutrition, non-smok-
ing, and regular exercise including referral to available pulmonary
rehabilitation programmes (Scullion 2013). Other preventative
strategies such as immunisation and infection control practices
can minimise future infection risk (King 2010).
Research
The development of new treatments and targeted therapies for
bronchiectasis has been slow; research trials have struggled with
recruitment numbers because of coexisting conditions in a rare
disease, and effectiveness of treatment for individuals with coex-
isting conditions remains unknown (Chalmers 2016). Duration
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of antibiotic treatment has been the focus of research and guide-
line recommendations; difﬁculties surround consensus, but agree-
ment has been reached regarding the value of sputum testing at
the beginning of antibiotic use (Polverino 2017). Use of long-term
antibiotics, particularly macrolides with ’antibiotic’ and ’anti-in-
ﬂammatory’ properties, has shown promise for reducing the fre-
quency of exacerbations; however care in screening for non-tuber-
culous mycobacteria (NTM) is needed to avoid issues of macrolide
resistance in NTM (Abo-Leyah 2017). Speciﬁc tools have been
developed to assess the severity of bronchiectasis these include the
FACED score (forced expiratory volume in one second (FEV1)
% predicted (F), age (A), chronic colonisation by Pseudomonas
aeruginosa (C), extension of the disease by radiological assessment
(E), and dyspnoea (D)), eFACED (FACED score including sig-
niﬁcant exacerbations(e)), and Bronchiectasis Severity Index (BSI)
and a quality of lifemeasure (Quality of Life - Bronchiectasis ques-
tionnaire); additional trials are required to validate their wider use
(Chalmers 2015; Minov 2015).
Description of the intervention
Traditionally, disease management has been a medically co-ordi-
nated activity encompassing diagnosis, clinical assessment, medi-
cation prescription, radiography, and pathology and other inves-
tigative testing, with goals of optimising treatment and monitor-
ing disease (Nathan 2006).
It has been over 50 years since the introduction of specialist nurs-
ing roles in the United States; Canada and the United Kingdom
were close behind in introducing similar models that have since
been rolled out across the world (Donald 2014). Reference to these
nurses encompasses different names across the world, including
specialist nurse, nurse practitioner, clinical specialist nurse, and
nursing consultant (Brodsky 2008). Different countries have re-
quired varying levels of skill and education to support these roles
(Brodsky 2008; Niziol 2008). Nursing extended practice roles are
predominantly complementary to, or are used to substitute for,
the usual (medical) model of care (Donald 2014).
Within respiratory medicine, the respiratory nurse specialist role
evolved in the early 1980s, initially to meet the needs of patients in
terms of rehabilitation and medication support, and have targeted
disease-speciﬁc areas such as cystic ﬁbrosis, asthma, COPD, and
occupational lung disease (Fletcher 2007; Niziol 2008).
Specialist nurses have advanced through additional education and
training to encompass roles previously within the domain of the
physician, resulting in blurring of professional boundaries and
provision of alternative models of care to the traditional medical
model (Niziol 2008). These initiatives have been embraced by
nurses, their medical colleagues, and health funders (Brodsky
2008).
How the intervention might work
Nurse-led consultation involves the specialist nurse taking on the
management role for stable disease as an alternative to the tradi-
tional doctor-led care model. This is not a new concept within
chronic disease, and disease specialties are reviewing cost-effec-
tiveness and equivalency of care with nurse-led models (Kilpatrick
2014). Studies speciﬁc to nurse-led care in bronchiectasis are lim-
ited; studies in respiratory medicine are presented below.
For asthma, a six-month randomised controlled trial saw 154
participants randomised to doctor-led or nurse-led care (Nathan
2006). Outcomes studied included numbers of exacerbations,
changes in peak ﬂow, quality of life (Asthma 20) questionnaire
scores, and clinic attendance (Nathan 2006). Follow-up asthma
care provided by the nurse specialist was as safe and effective as
that provided by the physician when a suitably trained nurse used
structured interventions including similar outpatient clinic timing
and access to independent prescribing (Nathan 2006).
For COPD, a review of types of nurse-led consultations showed
nurses in advanced practice roles recommending both pharma-
cological and non-pharmacological treatment and autonomously
functioning in diagnostic and follow-up roles (Fletcher 2013). A
randomised controlled trial involving 187 participants looked at
the effects on patient outcomes of transferring outpatient doctor
care to a respiratory nurse for stable patients with COPD (Vrijhoef
2007). This study showed that nurses working under a protocol
were effective in improving patients’ subjective knowledge and
satisfaction. Nurse-led and doctor-led care were comparable for
FEV1, body mass index (BMI), smoking status, health status, ob-
jective knowledge, and compliance, but cost increases for addi-
tional consultations were noted (Vrijhoef 2007).
For moderate to severe obstructive sleep apnoea, a multi-centre
randomised controlled non-inferiority trial compared health out-
comes of nurse-led care versus doctor-led care. The nurse-led ap-
proach used a simpliﬁed diagnostic and management model to
initiate in-home sleep study and treatment and to manage follow-
up. Data showed that nurse-led care was not inferior to physician-
led care in continuous positive airway pressure (CPAP) adherence,
quality of life, and patient satisfaction (Antic 2009), but offered
an effective strategy to reduce wait times for sleep study and to
free up physician clinics; also, costs were reduced and access to
treatment and devices was improved for trial participants (Antic
2009).
Specialist nurses in the role of alternative providers of usual (med-
ical) care have previously proved mostly equivalent for outcomes
related to patients and health systems (Kilpatrick 2014). Evi-
dence suggests that cost savings and resource use may be im-
proved through the use of specialist nurses in an outpatient con-
text (Kilpatrick 2014).
Why it is important to do this review
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Specialist nursing roles are gaining traction within the current
health service climate, but little is known about outcomes of nurse-
led care compared with outcomes of care delivered by doctors and
the cost implications of using either model. Systematic reviews
examining specialist nursing roles in a variety of healthcare set-
tings and specialisations are amassing a growing body of knowl-
edge (Donald 2014). To date, inconsistencies in reporting of study
methods and differences in nursing education, roles, and expe-
riences have made it difﬁcult to discern any formal conclusions,
other than that more rigorous research is required (Donald 2014).
This systematic review seeks to evaluate currently available evi-
dence from randomised controlled trials exploring management
of bronchiectasis - both chronic and acute episodes - within the
context of a nurse-led model.
O B J E C T I V E S
To compare the effectiveness of nurse-led care versus doctor-led
care in the management of stable bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of parallel and
cross-over design.We considered papers published in all languages.
Types of participants
We included studies in which adult or child participants had com-
puted tomography-deﬁned bronchiectasis.
Types of interventions
Interventions include specialist care managed or delivered by a
nurse who provides chronic disease management for bronchiec-
tasis through a minimum of two contacts over separate days. Ex-
cluded were studies solely focused on inpatient or immediate post-
procedural care. This systematic review compared nurse-led care
versus the usual care delivery model of doctor-led care.
Types of outcome measures
Primary outcomes
1. Exacerbations requiring treatment with antibiotics* (self-
reported and physician/specialist nurse reported)
2. Hospital admissions
3. Emergency department attendance
Secondary outcomes
1. Cost-effectiveness
2. Quality of life measures
3. Satisfaction (patient and general practitioner (GP))
4. Exercise capacity
5. Mortality
6. Lung function, such as FEV1 and forced vital capacity
(FVC)
*Nurse was accredited to prescribe antibiotics; post-clinic review
nurse met with consultant regarding all clinical decisions.
Patients were taught signs and symptoms that indicate when an-
tibiotics for exacerbation of bronchiectasis should be initiated.
They self-reported their use of antibiotics between clinic appoint-
ments.
Search methods for identification of studies
Electronic searches
We identiﬁed trials using the Cochrane Airways Trials Register,
which is maintained by the Information Specialist for the Group.
The Cochrane Airways Trials Register contains studies identiﬁed
from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies Online (crso.cochrane.org).
2. Weekly searches of MEDLINE Ovid SP 1946 to date.
3. Weekly searches of Embase Ovid SP 1974 to date.
4. Monthly searches of PsycINFO Ovid SP.
5. Monthly searches of Cumulative Index to Nursing and
Allied Health Literature (CINAHL) EBSCO.
6. Monthly searches of Allied and Complementary Medicine
(AMED) EBSCO.
7. Handsearches of the proceedings of major respiratory
conferences.
We identiﬁed studies contained in the Trials Register using search
strategies based on the scope of Cochrane Airways. We have pro-
vided details of these strategies, as well as a list of handsearched
conference proceedings, in Appendix 1. See Appendix 2 for search
terms used to identify studies for this review.
We conducted the latest search in March 2018.
Searching other resources
We searched the bibliography of the included study for rele-
vant trials that were not identiﬁed by the search strategy. We
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searched online clinical trials registries, including the International
Standard Registered Clinical/social sTudy Number (ISRCTN)
Registry from Controlled Clinical Trials (www.controlled-tri-
als.com), government registries (clinical trials.gov), and the Inter-
national Clinical Trials Registry Platform (ICTRP) search portal
of World Health Organization (WHO) registries (www.who.int/
trialsearch), for completed and ongoing studies.
Data collection and analysis
Selection of studies
Two review authors (KL andKR) independently scanned the titles,
abstracts, and keywords of papers identiﬁed from the searches.We
retrieved articles of potential relevance and reviewed the full text
for consideration of inclusion.
We reached consensus (after discussion) on whether all indepen-
dently classiﬁed citations and full-text studies obtained should be
included or excluded.
Both review authors (KL and KR) then applied inclusion criteria
to determine which papers should be included in the review and
should undergo data extraction. Inclusion criteria were developed
on the basis of types of studies, participants, interventions, and
outcomes identiﬁed.
Data extraction and management
One of the two review authors extracted all study data, the second
review author veriﬁed the data. KL and KVC independently per-
formed the risk of bias assessment.
Assessment of risk of bias in included studies
Two review authors (KL and KVC) independently assessed the
included study for risk of bias related to:
1. sequence generation;
2. allocation sequence concealment;
3. blinding of participants and personnel;
4. blinding at outcome measurement;
5. incomplete outcome data;
6. selective outcome reporting; and
7. other reporting biases.
Measures of treatment effect
We extracted continuous and dichotomous outcome data and
would have analysed them using standard statistical techniques
with a ﬁxed-effect model had we identiﬁed a sufﬁcient number
of included studies for pooling in the meta-analysis. If signiﬁ-
cant heterogeneity was found, we would have used a random-ef-
fects model. For continuous outcomes, we would have calculated
mean differences (MDs) with 95% conﬁdence intervals (CIs) and
would have pooled values as MDs or standardised mean differ-
ences (SMDs) for rates presented as rate ratios. For dichotomous
outcomes, we would have calculated risk ratios (RRs) with 95%
CIs.
We would have performed a narrative synthesis for each study had
we included more than one. We would have combined all trials
using Review Manager software.
Unit of analysis issues
We considered a mixture of cross-over and parallel studies for
inclusion in the review, with the potential for unit of analysis issues
to occur had we found sufﬁcient studies for pooling of results.
We planned to use the generic inverse variance (GIV) method
(by entering effect estimates and their standard errors) to adjust
for unit of analysis errors when meta-analysing the data, as per
Section 7.7.7 of theCochrane Handbook for Systematic Reviews and
Interventions, hadwe foundmore than one study to allow formeta-
analysis (Higgins 2011).
Dealing with missing data
We evaluated missing information regarding participants on an
available case analysis basis, as described in Chapter 16.2.2 of
the Cochrane Handbook for Systematic Reviews and Interventions
(Higgins 2011). If statistics essential for analysis were missing (e.g.
group means and standard deviations for both groups were not
reported) and could not be calculated from other data, we planned
to contact the study authors to requestmissingdata.We considered
loss of participants that occurred before baseline to have no effect
on eventual outcome data provided by the study. We assessed and
discussed on an intention-to-treat basis any losses that occurred
after baseline measurements had been taken.
Assessment of heterogeneity
Had we identiﬁed sufﬁcient studies, we would have assessed sta-
tistical heterogeneity using a combination of tests, including an I²
statistic and visual inspection of the data. If we had included 10
or more studies, we would have also used funnel plots. We would
have considered the Der-Simonian and Laird method of analysis
presented with a P value less than 0.05 as statistically signiﬁcant.
In the presence of signiﬁcant heterogeneity, we would have re-
analysed data using both ﬁxed-effect and random-effects models.
Assessment of reporting biases
We planned to examined reporting biases by using a funnel plot,
if we were able to meta-analyse 10 or more studies.
Data synthesis
We analysed trial data using RevMan 5.1.
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Subgroup analysis and investigation of heterogeneity
If we had included a sufﬁcient number of studies, we would have
performed the following subgroup analyses.
1. Hospital versus community-based nursing care.
2. Adults versus children.
Sensitivity analysis
We planned to perform a sensitivity analysis to explore effects of
bias derived from study methods on review ﬁndings. However, we
did not conduct a sensitivity analysis because we included only
one study, which we did not judge to be at high risk of bias for
sequence generation and allocation concealment.
R E S U L T S
Description of studies
Characteristics of included studies and Characteristics of excluded
studies are reported in the respective tables.
Results of the search
We identiﬁed 34 studies using search methods - 20 citations from
the literature search, and 14 through other source searches. A to-
tal of 31 studies remained when we had removed duplicates. We
excluded 26 records after title and abstract screening. We consid-
ered ﬁve studies relevant and screened them for eligibility, then ex-
cluded four studies. Only one study met review inclusion criteria
(Sharples 2002; see Figure 1).
Figure 1. Study flow diagram.
Included studies
We have reported details of the included study in the
Characteristics of included studies table and reasons for exclusion
of four studies in the Characteristics of excluded studies table.
Study design
The included study - Sharples 2002 - investigated the efﬁcacy of
nurse specialist care in bronchiectasis using a randomised, single-
centre, cross-over design. This study was conducted in the United
Kingdom and was published in 2002.
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Participant characteristics
A total of 149 patients with bronchiectasis from the Lung Defence
Clinic were identiﬁed, 40 of whom were unsuitable for inclusion;
seven additional participants declined or did not participate in the
recruitment process. From the remaining 102 eligible participants,
investigators randomised the ﬁrst 80 participants to attend the
clinic. All participants were ≥ 18 years of age, and mean partici-
pant age was 58.3 ± 13.3 years. The study included 55 female par-
ticipants, and the diagnosis of bronchiectasis was conﬁrmed for all
participants by high-resolution computed tomography (HRCT).
Participants were recruited from a bronchiectasis outpatient clinic.
Trials included only stable patients with an established manage-
ment plan*. Exclusion criteria comprised a life expectancy of less
than two years, expected transplant listing within the two-year
study period, FEV1 < 30% predicted, and other signiﬁcant co-
morbidities that would modify themanagement of bronchiectasis.
Data were obtained for 77 participants following two deaths and
inability of one participant to complete tests.
Investigators allocated 39 participants to nurse-led care in the in-
tervention arm and the remaining 41 participants to doctor-led
care during the year-long treatment period.
*The management plan was not speciﬁcally deﬁned but was inclu-
sive of best practice recommendations including physiotherapy,
medication compliance, and use of antibiotics (Sharples 2002).
Intervention characteristics
Patients, on arrival to the outpatient clinic, received routine test-
ing followed by consultation with a nurse practitioner or a doctor.
Consultation involved clinical assessment, review of history, phys-
ical examination, and discussion of a treatment management plan
for bronchiectasis. Appropriate changes to the management plan
were made, and additional tests such as X-ray and blood testing
performed. The nurse practitioner or the doctor had the discretion
to determine frequency of follow-up appointments on the basis
of a protocol that included weekly appointments for those given
intravenous antibiotics at home, fortnightly appointments to as-
sess results of antibiotic courses, and appointments every three to
six months for routine monitoring of the patient’s disease. When
participants were randomised, they were assigned their appropri-
ate contact person (nurse practitioner or doctor) and were encour-
aged to telephone that contact person with disease or management
queries. The nurse practitioner had the same autonomy as the
doctor to bring patient appointments forward and to recommend
general practitioner review or emergency medication commence-
ment. The nurse practitioner did not have authority to manage
other systemic problems outside management of bronchiectasis,
and admission to hospital for these issues was referred to the con-
sultant. Additional education, referrals, and use of speciﬁc sputum
clearance techniques were not reported.
To ensure patient safety, a supervision mechanism was included
as part of the study design whereby the nurse practitioner had
a detailed discussion with a consultant within 24 hours of the
clinic to detailmanagement decisions. If the consultantwould have
made a different management decision, the patient was contacted
regarding a change in treatment.
Excluded studies
Four studies appeared relevant from the initial screening process;
however on further investigation, they did not meet all criteria
for inclusion. We excluded these studies from analysis for the fol-
lowing reasons. Two studies were randomised controlled trials in-
volving patients with COPD (Bergner 1988; Cockcroft 1987).
Both studies looked at home care nursing as the intervention, with
nurses in a supportive role. Levy 2000 was a randomised controlled
trial in which participants had asthma. The intervention patient
education provided by a respiratory nurse was compared with no
education and standard follow-up with the general practitioner.
Maa 2007 met criteria for inclusion in that this was a randomised
controlled trial with participants who had bronchiectasis; however
this was not a nurse-led care comparison study. The nurse played
a complementary role in supervising acupressure treatment.
Risk of bias in included studies
Full details of our risk of bias judgements can be found in the
“Risk of bias” section at the end of each Characteristics of included
studies table and in Figure 2.Overall, themethodological certainty
of the study was satisfactory. Two independent review authors
(KL and KC) reached agreement regarding assessment of study
certainty.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Review authors considered generation of randomisation sequence
as having unclear risk in Sharples 2002. Investigators mentioned
but did not describe randomisation. Review authors considered al-
location concealment to be adequately reported in Sharples 2002.
This presented low risk of bias with the use of numbered opaque
envelopes.
Blinding
Blinding of participants and personnel did not occur; this was
considered to confer unclear risk of bias because the design of
this interventionmade blinding impossible. The effect of knowing
which groups the participant was assigned to and crossed over to
is unknown.
Lack of blinding of assessment outcomes led to the conclusion of
high risk of detection bias.
Incomplete outcome data
Overall the level of study completion was high. Two patient deaths
had occurred after the ﬁrst 12 months of the study; a patient given
nurse-led care died from perforated bowel, and a patient receiving
doctor-led care died from respiratory failure. Most participants
completed clinical assessment.One patientwas unable to complete
lung function and exercise testing owing to a rib fracture not related
to his bronchiectasis. Two other patients did not complete the
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exercise test; one at 12 months had a fractured toe, and one at 24
monthswas too sick to complete testing. Both of these participants
had received doctor-led care before the time of their assessment.
Quality of life was not assessed in two different participants, one
at 12 months and one at 24 months; both had received nurse-led
care during the assessment period. Six participants did not cross
over to nurse-led care in the second year, as they were no longer
considered to have stable bronchiectasis. These participants were
still included in the trial on an intention-to-treat basis. Trialists
reported that a secondary analysis excluding participants produced
almost identical results. These results were not published in the
original article, and trial authors did not respond to attempts to
contact them. They reported attrition with reasons and a high
completion rate; therefore we judged this domain as having low
risk of bias.
Selective reporting
Investigators tested changes between time periods; however, they
observed effects with changes in the economic analysis in the sec-
ond year of the trial and mentioned these results in the discussion
but did not report them in the results. Owing to the cross-over
design with no washout period, we could not exclude the presence
of a carryover effect. This may have an impact on data pertaining
to exacerbations and hospital admissions in particular, but could
also effect FEV1 and exercise capacity. Trialists performed post hoc
analysis for carryover of clinical outcomes but stated that these
results were non-signiﬁcant and did not report further on them.
Attempts to seek clariﬁcation from study authors of post hoc anal-
ysis and ﬁrst year data were unsuccessful. Cost changes between
the ﬁrst and second years of the study could be related to learned
effect or selection effect, given that six participants did not cross
over to nurse-led care (Sharples 2002). For all of these reasons, we
judged this domain as having high risk of bias.
Other potential sources of bias
We did not identify other potential sources of bias in this study.
Effects of interventions
See: Summary of findings for the main comparison Nurse-
led care compared with doctor-led care for management of
bronchiectasis
See Summary of ﬁndings for the main comparison for the main
comparison of nurse-led care versus doctor-led care for manage-
ment of stable bronchiectasis.
No meta-analysis or sensitivity analysis was possible because only
a single study was identiﬁed (Sharples 2002). To eliminate ques-
tions regarding carryover effects of doctor-led/nurse-led care, we
attempted to contact the authors of this study to request data from
the ﬁrst 12 months of the study. We received no response, so we
reviewed outcomes over the 24-month study period including the
12-month crossover time periods. We have presented narrative
data from the published paper.
Exacerbations requiring treatment with antibiotics
Infective exacerbations were reported by patients and were not
veriﬁed by the physician or nurse. The number of infective exacer-
bations experienced by participants during nurse practitioner-led
care was 262 in 79.4 patient-years of follow-up, compared with
238 in 77.8 years during doctor-led care (rate ratio 1.09, 95% CI
0.91 to 1.30; low-certainty evidence; Analysis 1.1).
Hospital admissions
During doctor-led care, investigators reported 42 admissions to
hospital compared with 66 during nurse-led care (rate ratio 1.52,
95% CI 1.04 to 2.23; low-certainty evidence; Analysis 1.2). Of
these, 23 and 43 re-admissions, respectively, were attributable to
bronchiectasis (rate ratio 1.59, 95% CI 0.75 to 3.39; P = 0.22;
Sharples 2002). Data show a statistically higher proportion of
hospital admissions in nurse-led care over the trial period.
Emergency department attendance
This was not reported.
Cost-effectiveness
Researchers assessed hospital admission, use of medication, and
clinic visits to determine cost-effectiveness of nurse-led versus doc-
tor-led care. Three drugs accounted for more than 80% of the dif-
ference in antibiotic utilisation, namely, intravenous meropenem
and ceftazidime and nebulised colistin. These drugs are infre-
quently used but are costly; this meant that the slight increase in
use among participants being cared for by the nurse was econom-
ically important. Most intravenous antibiotics were prescribed for
treatment of patients with Pseudomonas infection, as per a well-
deﬁned protocol. Medical staff pre-authorised all hospital admis-
sions and determined length of stay of these participants (Table
1). Nurse-led care resulted in signiﬁcantly higher costs per patient
compared with doctor-led care, largely owing to differences in the
number of hospital admissions and increased use of intravenous
and nebulised antibiotics. Total cost of nurse-led care per patient
in the ﬁrst year was £5202, and total cost was £3262 in the sec-
ond year. Costs of doctor-led care per patient in the ﬁrst year were
£2577 and in the second year £2851 (Sharples 2002).
Nurse-led clinic appointments lasted on average 26 minutes com-
pared with 20 minutes for doctor-led care (Sharples 2002). Nurses
averaged 5.06 clinic visits per patient compared with 4.48 for doc-
tors (Table 1).
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Quality of life measures
Triaists administered St. George’s Respiratory Questionnaire
(SGRQ). Results show no signiﬁcant differences but signiﬁcant
uncertainty because of wide conﬁdence intervals for each of the
scores for symptoms, control, or impact, or for total score (Analysis
1.3; Analysis 1.4; Analysis 1.5; Analysis 1.6). One patient in a
nurse-led care group refused to complete quality of life interviews
at 12 months.
Satisfaction (patient and GP)
Study authors asked participants to rate their satisfaction with
nurse-led and doctor-led care and analysed 12 individual state-
ments related to the consultation. Statistically signiﬁcant differ-
ences favoured the nurse practitioner in terms of communication
and time spent with patients (Table 2).
Exercise capacity
Results on exercise capacity were unclear owing to wide conﬁ-
dence intervals in distance walked during a 12-minute walking
test (12MWT) between people receiving nurse-led care and those
given doctor-led care (low-certainty evidence; Analysis 1.7).
Mortality
Twopatients died after the 12-month follow-up. The patient given
nurse-led care died from a perforated bowel, and the patient receiv-
ing doctor-led care died from end-stage respiratory failure (low-
certainty evidence; Sharples 2002).
Lung function
Results show no statistically signiﬁcant differences in FEV1/FVC
percent predicted or distance walked between nurse-led and doc-
tor-led care in the two treatment periods (low-certainty evidence;
Analysis 1.8; Analysis 1.9).
D I S C U S S I O N
Summary of main results
The primary aim of this review was to assess the effectiveness of
nurse specialist care compared with traditional doctor-led care for
people with bronchiectasis. The evidence presented in this review
is insufﬁcient to show if nurse-led or doctor-led care is better,
worse, or the same.
Sharples 2002 randomised 80 people with stable bronchiectasis to
receive care from either the nurse practitioner or a physician for
one year. After one year, the group crossed over to the other practi-
tioner. This trial is now old, and since it was published, bronchiec-
tasis guidelines have been produced for the ﬁrst time. Outcome
data related to infective exacerbation rate, quality of life, exercise
capacity, and lung function show little between-group difference
but do not demonstrate equivalence. Patient satisfaction showed
signiﬁcant differences in favour of the nurse practitioner - which
trial authors postulated may be due to improved communication
and increased time spent with patient (Sharples 2002). An increase
in hospital admissions for nurse-led care was evident when paired
data from both arms of the trial were considered. Nurse-led care
in the ﬁrst year of the study incurred increased costs from hospital
admissions and use of antibiotics (Sharples 2002). A paucity of
data contributed to wide conﬁdence intervals for all outcomes,
reﬂecting uncertainty in the results and low certainty of evidence.
The cross-over design as applied to temporary effects such as the
patient review is a suitable evaluation when directed to a stable
chronic condition such as bronchiectasis. Advantages of this de-
sign include that each patient acts as his or her own control (elim-
inating participant variation amongst participants), fewer partici-
pants are required for assessment, and all participants receive the
intervention (Higgins 2011). The potential for a carryover effect
without a washout period between treatments cannot be excluded
as a potential bias (Higgins 2011).
Overall completeness and applicability of
evidence
Despite an extensive literature search and increasing utilisation of
nursing specialist roles in health care, only one study conducted
within this 15-year time framemet the inclusion criteria for this re-
view. Since 2002, bronchiectasis guidelines have been introduced
and practices have changed. Additional research into classiﬁcation
of bronchiectasis through use of severity scores, as well as new in-
haled antibiotic agents and successful use of macrolides as treat-
ment options, have added to management strategies. Future de-
velopment of targeted therapies in line with underlying causes of
bronchiectasis are under investigation (Chalmers 2015).
Additional costs
Sharples 2002 reports signiﬁcant additional resource use in nurse-
led care related to increased hospital admissions during the ﬁrst
year of the trial. However, the difference between nurse-led care
and doctor-led care was substantially less in the second year of
nurse specialist care. Study authors suggest this may be a learned
effect, as the nurse becamemore familiar with the outpatient clinic
management role. After receiving additional training, it was the
nurses’ ﬁrst year of managing people in a clinic, but the doctors
leading care groups had at least three years’ experience. Trial au-
thors postulated that further modiﬁcation to the protocol may re-
duce the cost difference further (Sharples 2002). Few studies of
14Nurse-led versus doctor-led care for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
good certainty have effectively shown that disease management
can affect healthcare utilisation and costs (Ofman 2004). A broad
systematic review of nurse-led clinics did show some favourable
results in terms of nurse-led care cost-effectiveness; however lim-
ited studies in this area have reduced the generalisability of these
results (Randall 2017). Case management in nurse-led clinics was
also shown to increase cost-effectiveness and to reduce hospital
admission (Randall 2017).
Antibiotic stewardship
The role of stewardship in the use of antibiotics is to maximise
clinical success and reduce unplanned consequences such as an-
tibiotic resistance (Garau 2014). People with bronchiectasis who
experience frequent exacerbations should have antibiotic choice
guided by sputum testing for microscopy, culture, and sensitivity
(Pasteur 2010; Polverino 2017). Colonisation with opportunistic
organisms such as Pseudomonas can occur in bronchiectasis, and
the decision to treat an individual with infection should be made
using clinically objective measures (i.e. presence of temperature,
general malaise) and, when possible, blood results indicating raised
C-reactive protein (CRP) or white cell count (WCC) (Brink 2016;
Garau 2014).
The role of non-pharmacological interventions such as self-man-
agement/chronic disease support and review of sputum clearance
techniques should be considered to optimise care (Garau 2014;
Pasteur 2010).
Protocol use
Use of a protocol by the nurse may have led to increased costs
through compliance with the recommended management path-
way. No evidence suggests that doctor-led care followed the same
protocol. Variance in decision making between the three doctors
involved in the study cannot be excluded (Sharples 2002). A man-
agement protocol would have been used in Sharples 2002 in the
absence of bronchiectasis guidelines, which were not released un-
til 2008 (Martinez-Garcia 2018). Auditing of British Thoracic
Society (BTS) guidelines for bronchiectasis management has re-
vealed lack of adherence to the guideline (Hill 2012; Hill 2014).
Few economic evaluations were reported before guideline release
(Garrison 2016); however it is expected that better management
through adherence to guidelines should lead to better health out-
comes (Polverino 2017). Further evaluation of protocol use/guide-
line adherence by clinicians is recommended to determine whether
costs reduce overtime and health outcomes are improved.
Hospital admissions
Hospital admissions were higher for the group receiving nurse-led
care. All admissions in nurse specialist care had to be authorised
by a consultant, and all admissions were considered appropriate
(Sharples 2002). This increase in cost may be attributed to the
experience of the nurse compared with that of the doctor. The
nurse practitioner had been trained to practice at an advanced
level but required additional training in the specialist aspect of
this disease before participating in the study. The doctor-led care
group included physicians with a minimum of two to three years
of consultative experience in caring for patients with respiratory
disorders.
Nurse training
The nursing role or its level of specialisation is not deﬁned within
the BTS guideline for bronchiectasis nor in the European Respi-
ratory Society (ERS) monograph, but the BTS guideline suggests
that nurses should be suitably trained to fulﬁl their role in the
management of bronchiectasis (Floto 2011; Pasteur 2010). The
advanced practice role of a specialist nurse in a tertiary setting in
Sharples 2002 was acknowledged in the guideline (Pasteur 2010).
Little has been written about nurses and their training in recent
guideline releases. The Spanish guideline has identiﬁed some of the
key nursing responsibilities, which include control of treatment
adherence, assessment of medication tolerance, inhaled medica-
tion education, maintenance of equipment, intravenous antibi-
otic administration, disease monitoring with spirometry, and spu-
tum clearance (Martinez-Garcia 2018). Introduction of guidelines
for management assists nurses in advanced or extended practice
roles to provide translational health care through integration of
guidelines into current practice when clinically judged appropriate
(Branham 2014). The costs of nurse training were also included
among study expenses.
Patient satisfaction
Patient satisfaction was greater for communication and time
spent with patient when nurse-led care was provided (Sharples
2002). Nurse interventions in complementary roles to doctor-
led care often include review of patient needs, education, self-
management, and additional referral to healthcare professionals
(Kilpatrick 2014). This approach is likely to be incorporated into
nurse-led care models, accounting for some of the extra time that
nurses spent with their patients (Vrijhoef 2007).
The generalisability of results presented in Sharples 2002 is limited
to the Lung Defence Clinic because no similar studies have been
conducted.
Quality of the evidence
The overall quality of the included study was low, but because
review authors identiﬁed only one study during the literature, we
have limited ability to conclude, beyond this study, that nurse-led
care in the management of stable bronchiectasis is more effective
than doctor-led care.
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Potential biases in the review process
No signiﬁcant biases were expected, or and none were found to
occur during the review process. Criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions were strictly fol-
lowed to limit potential biases during screening, data extraction,
and data analysis (Higgins 2011). Two review authors indepen-
dently assessed risk of bias and resolved conﬂicts by discussion
with a third review author.
We attempted to correspond with study authors but received no
reply. None of the authors of this review reported conﬂicts of
interests, ﬁnancial or otherwise.
Agreements and disagreements with other
studies or reviews
Wedid not identify any new studies via updated searches; therefore
our conclusions have not substantively changed in this update.We
have updated the background section to present a contemporary
picture of bronchiectasis and to provide examples of respiratory
nurse-led care versus doctor-led care for a variety of respiratory
diseases. Cochrane methods have changed since the review was
last completed, and we have updated this review to bring it in line
with current recommendations.
Respiratory specialist nurses may focus on a speciﬁc single disease
or may have a broader chronic disease scope of practice (Fletcher
2013). For other respiratory conditions such as asthma, chronic
obstructive pulmonary disease (COPD), and sleep disorders, spe-
cialist nurses have been shown to be comparable to doctors car-
ing for stable patient groups (Antic 2009; Fletcher 2013; Nathan
2006). Expanding the scope of this review to make it inclusive of
respiratory specialist nurses functioning in an alternative role to
doctors in providing care may improve the yield of suitable stud-
ies and improve the body of evidence to permit a determination
about specialist nurse care.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review has been unable to demonstrate the clinical and cost
effectiveness of nurse specialist care when compared with doctor-
led care for management of stable bronchiectasis, based on ﬁnd-
ings of a single study. Uncertainty remains owing to the paucity
of evidence surrounding nurse-led care in the management of
bronchiectasis. The study showed uncertainty related to outcomes
of exacerbation, quality of life, exercise, mortality, and lung func-
tion. Patient satisfaction improved with nurse-led care; however
costs increased owing to admissions and use of medication. It is
unknown whether costs reported in the study conducted in 2002
are a true reﬂection of the average cost of providing care for people
living with bronchiectasis at the current time, according to up-
dated guidelines and clinical practice.
Implications for research
Widespread use of nurse-led care models in health care still lacks
the research rigour needed to show cost-effectiveness, and ﬁndings
in current research are unclear (Lopatina 2017). Issues surrounding
the uniqueness of practice roles and speciﬁcity for disease groups
make it difﬁcult to know how cost-effective they are beyond the
group tested (Lopatina 2017). A standard approach based on a
validated economic evaluation tool may facilitate generalisation.
In Sharples 2002, the nurse followed a protocol developed from
recommended management practices of the day.Wider adherence
to the protocol by the nurse or by the doctor was not reported.
Future studies must measure compliance with protocols to deter-
mine efﬁcacy with exacerbations and hospital admissions.
Long-term studies of nurse specialist care in bronchiectasis are
required to determine:
1. cost-effectiveness of nurse-led care in bronchiectasis;
2. whether bronchiectasis guidelines are followed and whether
this contributes to an increase in cost; and
3. whether bronchiectasis management in other clinical
settings such as inpatient and outreach nursing is effective.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Sharples 2002
Methods Country: United Kingdom
Design: randomised controlled trial, single centre, cross-over study. No washout phase
Study objective: to assess feasibility and safety of nurse-led outpatient clinic and to
compare cost-effectiveness of nurse-led vs doctor-led care
Methods of analysis: paired student’s t tests, means, conﬁdence intervals
Exacerbation and admission: Poisson distribution and modes of care comparison using
likelihood ratios
Patient satisfaction: Wilcoxon signed rank test, McNemar test
Cost analysis: paired non-parametric bootstrap analysis
Clustering adjustments made: not relevant
Participants Eligible for study: 80
Randomised: 39 nurse-led care, 41 doctor-led care
Completed: 37 nurse-led care, 40 doctor-led care
Age, years: nurse/doctor 63.7, doctor/nurse 53.1; mean age 58.3 ± 13.3 years
Gender: male/female 25/55
Bronchiectasis diagnosis: conﬁrmed by high-resolution computed tomography
Recruitment: outpatient clinic attendance with established management plan
Comorbidities: no detail provided regarding comorbid conditions
Exclusion criteria: life expectancy < 2 years, need for transplant listing within 2 years,
FEV1 < 30% predicted, other signiﬁcant pathology that would modify the management
of bronchiectasis
Interventions Intervention description: nurse specialist-led care
Control description: doctor-led care
Duration of intervention: two 1-year care blocks
Setting: outpatient
Outcomes Prespeciﬁed outcomes: FEV1, FVC, exacerbation rates, hospital admissions, quality of
life, cost-effectiveness, exercise capacity, 12MWT, withdrawals and dropouts, nurse au-
tonomy, participant and GP satisfaction; consultation: type, length, and venue; partici-
pant compliance
Follow-up period: 1 year, then cross-over
Notes Funding: NHS R&D Health Technology Assessment Programme
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation mentioned but methods
not described
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Sharples 2002 (Continued)
Allocation concealment (selection bias) Low risk Numbered opaque envelopes used
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding did not occur; blindness was not
possible, given it is part of the interven-
tion. Impact of knowing group assignment
is unclear. Carryover effects from ﬁrst year
of study may have occurred when crossed-
over
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding did not occur.
Incomplete outcome data (attrition bias)
All outcomes
Low risk High level of completion; attrition reported
with reasons
Selective reporting (reporting bias) High risk Changes between time periods were tested;
however effects were observed in the eco-
nomic analysis during the second time pe-
riod; post hoc analyses occurred for car-
ryover of clinical outcomes but were not
reported. Selection effect cannot be ruled
out, given that 6 participants did not cross-
over to nurse-led care
Other bias Low risk No other biases identiﬁed
12MWT: 12-minute walk test; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; GP: general practitioner;
NHS: National Health Service; R&D: Research and Development.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bergner 1988 Randomised controlled trial - participants had a conﬁrmed diagnosis of chronic obstructive pulmonary disease
Cockcroft 1987 Randomised controlled trial - participants with chronic obstructive airways disease were recruited
Levy 2000 Randomised controlled trial of specialist nurse education in asthma
Maa 2007 Randomised trial of nurse in complementary alternative medicine role utilising acupressure as treatment for
participants with bronchiectasis
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D A T A A N D A N A L Y S E S
Comparison 1. Nurse-led versus physician-led care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Infective exacerbations (per
patient per year)
1 Rate Ratio (Fixed, 95% CI) Totals not selected
2 Admissions per patient per year 1 Rate Ratio (Fixed, 95% CI) Totals not selected
3 SGRQ - symptoms 1 Mean Difference (Fixed, 95% CI) Totals not selected
4 SGRQ - control 1 Mean Difference (Fixed, 95% CI) Totals not selected
5 SGRQ - impact 1 Mean Difference (Fixed, 95% CI) Totals not selected
6 SGRQ - total scores 1 Mean Difference (Fixed, 95% CI) Totals not selected
7 Exercise capacity: 12-minute
walk distance, metres
1 Mean Difference (Fixed, 95% CI) Totals not selected
8 FEV1 (% predicted) 1 Mean Difference (Fixed, 95% CI) Totals not selected
9 FVC (% predicted) 1 Mean Difference (Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Nurse-led versus physician-led care, Outcome 1 Infective exacerbations (per
patient per year).
Review: Nurse-led versus doctor-led care for bronchiectasis
Comparison: 1 Nurse-led versus physician-led care
Outcome: 1 Infective exacerbations (per patient per year)
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Sharples 2002 0.0862 (0.0899) 1.09 [ 0.91, 1.30 ]
0.2 0.5 1 2 5
Favours nurse Favours doctor
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Analysis 1.2. Comparison 1 Nurse-led versus physician-led care, Outcome 2 Admissions per patient per
year.
Review: Nurse-led versus doctor-led care for bronchiectasis
Comparison: 1 Nurse-led versus physician-led care
Outcome: 2 Admissions per patient per year
Study or subgroup log [Rate Ratio] Rate Ratio Rate Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Sharples 2002 0.4187 (0.1956) 1.52 [ 1.04, 2.23 ]
0.1 0.2 0.5 1 2 5 10
Favours nurse Favours doctor
Analysis 1.3. Comparison 1 Nurse-led versus physician-led care, Outcome 3 SGRQ - symptoms.
Review: Nurse-led versus doctor-led care for bronchiectasis
Comparison: 1 Nurse-led versus physician-led care
Outcome: 3 SGRQ - symptoms
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Sharples 2002 -1.4 (2.347) -1.40 [ -6.00, 3.20 ]
-10 -5 0 5 10
Favours nurse Favours doctor
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Analysis 1.4. Comparison 1 Nurse-led versus physician-led care, Outcome 4 SGRQ - control.
Review: Nurse-led versus doctor-led care for bronchiectasis
Comparison: 1 Nurse-led versus physician-led care
Outcome: 4 SGRQ - control
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Sharples 2002 -1.74 (1.398) -1.74 [ -4.48, 1.00 ]
-10 -5 0 5 10
Favours nurse Favours doctor
Analysis 1.5. Comparison 1 Nurse-led versus physician-led care, Outcome 5 SGRQ - impact.
Review: Nurse-led versus doctor-led care for bronchiectasis
Comparison: 1 Nurse-led versus physician-led care
Outcome: 5 SGRQ - impact
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Sharples 2002 -1.8 (1.4286) -1.80 [ -4.60, 1.00 ]
-10 -5 0 5 10
Favours nurse Favours doctor
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Analysis 1.6. Comparison 1 Nurse-led versus physician-led care, Outcome 6 SGRQ - total scores.
Review: Nurse-led versus doctor-led care for bronchiectasis
Comparison: 1 Nurse-led versus physician-led care
Outcome: 6 SGRQ - total scores
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Sharples 2002 -1.7 (1.1735) -1.70 [ -4.00, 0.60 ]
-4 -2 0 2 4
Favours nurse Favours doctor
Analysis 1.7. Comparison 1 Nurse-led versus physician-led care, Outcome 7 Exercise capacity: 12-minute
walk distance, metres.
Review: Nurse-led versus doctor-led care for bronchiectasis
Comparison: 1 Nurse-led versus physician-led care
Outcome: 7 Exercise capacity: 12-minute walk distance, metres
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Sharples 2002 18 (15.8166) 18.00 [ -13.00, 49.00 ]
-100 -50 0 50 100
Favours doctor Favours nurse
25Nurse-led versus doctor-led care for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 Nurse-led versus physician-led care, Outcome 8 FEV1 (% predicted).
Review: Nurse-led versus doctor-led care for bronchiectasis
Comparison: 1 Nurse-led versus physician-led care
Outcome: 8 FEV1 (% predicted)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Sharples 2002 0.2 (0.9184) 0.20 [ -1.60, 2.00 ]
-10 -5 0 5 10
Favours doctor Favours nurse
Analysis 1.9. Comparison 1 Nurse-led versus physician-led care, Outcome 9 FVC (% predicted).
Review: Nurse-led versus doctor-led care for bronchiectasis
Comparison: 1 Nurse-led versus physician-led care
Outcome: 9 FVC (% predicted)
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Sharples 2002 -0.02 (0.7245) -0.02 [ -1.44, 1.40 ]
-4 -2 0 2 4
Favours doctor Favours nurse
26Nurse-led versus doctor-led care for bronchiectasis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L T A B L E S
Table 1. Cost-effectiveness
Resource Nurse-
led care (mean vis-
its per participant)
Nurse-
led care (mean cost
per participant, £)
Doctor-
led care (mean vis-
its per participant)
Doctor-
led care (mean cost
per participant, £)
Difference (SD, £)
Nurse-led clinics 4.61 180 0 0 180 (158)
Doctor-led clinics 0.45 25 4.48 217 -192 (199)
Procedures 0.13 61 0.11 54 7 (376)
Imaging 1.14 47 0.76 45 1 (112)
Other tests 24.58 260 18.94 222 37 (257)
Antibiotics
(intravenous)
23 (days) 879 16 (days) 523 356 (1452)
Antibiotics (oral) 222 (days) 684 201 (days) 524 161 (695)
Bronchodilators 461 (days) 213 435 (days) 193 20 (179)
Corticosteroids 238 (days) 278 219 (days) 258 20 (181)
Other drugs 212 (days) 180 190 (days) 155 25 (194)
Inpatient 6.46 (days) 1338 2.36 (days) 477 861 (2755)
Day case 0.11 43 0.05 16 27 (170)
GP visits 1.11 20 1.40 26 -6 (33)
Total 4208 2711 1498
(688 to 2674)
SD: standard deviation.
Table 2. Participant satisfaction with consultation
Comments Nurse practitioner better,
number, (%)
Doctor better, number (%) P value
It was sometimes difﬁcult to
discuss your problems with the
doctor/nurse practitioner
11/76 (14.5) 1/76 (1.3) 0.006
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Table 2. Participant satisfaction with consultation (Continued)
The doctor/nurse practitioner
explained clearly what is wrong
7/74 (9.5) 0/74 (0) 0.016
The doctor/nurse practitioner
examined you thoroughly when
necessary
6/70 (8.6) 0/70 (0) 0.031
The doctor/nurse practitioner
should tell youmore about your
illness/condition and treatment
7/59 (11.9) 3/59 (5.1) 0.344
The doctor/nurse practitioner
made you feel at ease.
2/75 (2.7) 1/75 (1.3) 1.000
There was not enough time to
discuss your problems with the
doctor/nurse
10/74 (13.5) 1/74 (1.4) 0.012
You felt conﬁdent the doctor/
nurse practitioner knew about
your medical history and your
care
7/74 (9.5) 1/74 (1.4) 0.070
Some-
times you felt that the doctor/
nurse practitioner should listen
more to what you said
5/69 (7.2) 2/69 (2.9) 0.453
The doctor/nurse practitioner
gave clear explanation about
any tests that you needed
4/75 (5.3) 1/75 (1.3) 0.375
You often came away from your
appointment wishing you’d
asked more questions
13/72 (18.1) 9/72 (12.5) 0.523
You felt youwere given a chance
to have an active part when dis-
cussing your illness/condition
4/73 (5.5) 0/73 (0.0) 0.125
There were frequent interrup-
tions during your consultation.
6/73 (8.2) 3/73 (4.1) 0.508
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Register of Trials
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
Embase (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Paciﬁc Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Bronchiectasis search
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1. exp Bronchiectasis/
2. bronchiect$.mp.
3. bronchoect$.mp.
4. kartagener$.mp.
5. (ciliary adj3 dyskinesia).mp.
6. (bronchial$ adj3 dilat$).mp.
7. or/1-6
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT ﬁlter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant studies from the Cochrane Airways Register of
Trials
#1 BRONCH:MISC1
#2 MeSH DESCRIPTOR Bronchiectasis Explode All
#3 bronchiect*
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Ambulatory Care
#6 MeSH DESCRIPTOR Nurses Explode All
#7 MeSH DESCRIPTOR Nursing
#8 “ambulatory care”
#9 nurs*
#10 doctor*
#11 “medical staff ”
#12 specialis*
#13 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 #4 and #13
[In search line #1, MISC1 denotes the field in the record where the reference has been coded for condition, in this case, bronchiectasis]
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WH A T ’ S N E W
Last assessed as up-to-date: 5 March 2018.
Date Event Description
5 March 2018 New citation required but conclusions have not changed Review structure and methods updated to match current
Cochrane standards. Background/discussion updated.
New review author team. Order of outcomes changed
5 March 2018 New search has been performed Literature search run. No new suitable studies found
H I S T O R Y
Protocol ﬁrst published: Issue 2, 2001
Review ﬁrst published: Issue 3, 2003
Date Event Description
3 July 2008 New search has been performed Update search run in July 2008; no new studies found
3 July 2008 Amended Converted to new review format
4 September 2002 New citation required and conclusions have changed Substantive amendments made
C O N T R I B U T I O N S O F A U T H O R S
KL and KR wrote the protocol with additional input from KVC. KL and KR assessed search results. KL and KVC-C entered data and
developed the discussion. FC and BJS contributed comments to the ﬁnal draft of the manuscript before submission to editorial.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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S O U R C E S O F S U P P O R T
Internal sources
• The review authors declare that no such funding was received for this systematic review, Other.
External sources
• The review authors declare that no such funding was received for this systematic review, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This review includes a new review author team.
Outcome measures include the following.
1. The new review author team reordered primary and secondary outcomes and included data on patient satisfaction and cost-
effectiveness not previously reported.
2. Hospital admission was changed to a primary outcome, in addition to exacerbations.
3. Lung function was changed to a secondary outcome, as it is unlikely to show signiﬁcant differences in stable bronchiectasis.
New methods include the following.
1. Since the last review, changes to search methods and standard airways protocol have occurred; these have been included in this
update.
2. Assessment of risk of bias has been updated. Results have been presented in the ’Summary of ﬁndings’ table.
In the previous review, the ﬁrst review author and Diana Bilton were involved in the only trial analysed in the review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Bronchiectasis [∗nursing]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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